Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow iTeos Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for iTeos Therapeutics, Inc.

ITOS

iTeos Therapeutics, Inc.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a biopharmaceutical company focused on developing immuno-oncology therapies targeting tumor resistance mechanisms. Its pipeline includes monoclonal antibodies and small molecules designed to enhance immune response against cancer, especially solid tumors. The company collaborates with GSK and others to advance clinical candidates, leveraging expertise in tumor biology, immunology, and translational medicine to create innovative cancer treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from iTeos Therapeutics, Inc.

1
1
iTeos Therapeutics, Inc. iTeos Therapeutics Reports No Revenue and $78.7 Million Net Loss for Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
iTeos Therapeutics, Inc. iTeos Therapeutics Reports $34.6 Million Net Loss in Q1 2025, Decreased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
iTeos Therapeutics, Inc. iTeos Therapeutics Reports $35 Million Revenue Increase Driven by Milestone Payment

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
iTeos Therapeutics, Inc. iTeos Therapeutics Reports 178% Revenue Growth, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments